Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
Starpharma Holdings LimitedTelephone
61.3.8532.2700
Address
4-6 Southampton Crescent Abbotsford, Victoria (VIC) 3067
Description
Starpharma Holdings Ltd. engages in the research, development, and commercialization of dendrimer products for pharmaceutical and healthcare applications. Its pipeline and products include SN38, cabazitaxel, docetaxel, radiopharmaceuticals, antibody-drug conjugates, and anti-infective products. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.09 - 0.19
Trade Value (12mth)
AU$18,243.00
1 week
-2.06%
1 month
-2.06%
YTD
-45.71%
1 year
-29.63%
All time high
2.52
EPS 3 yr Growth
-60.20%
EBITDA Margin
-169.40%
Operating Cashflow
-$7m
Free Cash Flow Return
-20.60%
ROIC
-24.10%
Interest Coverage
N/A
Quick Ratio
4.60
Shares on Issue (Fully Dilluted)
412m
HALO Sector
Healthcare
Next Company Report Date
20-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.14
Date | Announcements |
---|---|
03 October 24 |
Notification of cessation of securities - SPL
×
Notification of cessation of securities - SPL |
03 October 24 |
Date of Annual General Meeting 2024
×
Date of Annual General Meeting 2024 |
16 September 24 |
Change of Director's Interest Notice - Dr Russell Basser
×
Change of Director's Interest Notice - Dr Russell Basser |
12 September 24 |
Starpharma Receives $5.5M R&D Tax Incentive Refund
×
Starpharma Receives $5.5M R&D Tax Incentive Refund |
09 September 24 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
02 September 24 |
Change in Director's Interest Notice - R Thomas
×
Change in Director's Interest Notice - R Thomas |
02 September 24 |
Change in Director's Interest Notice - David McIntyre
×
Change in Director's Interest Notice - David McIntyre |
28 August 24 |
Application for quotation of securities - SPL
×
Application for quotation of securities - SPL |
27 August 24 |
Change in substantial holding
×
Change in substantial holding |
22 August 24 |
Annual Report to shareholders
×
Annual Report to shareholders |
22 August 24 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
16 August 24 |
Change in substantial holding
×
Change in substantial holding |
02 August 24 |
Change in substantial holding
×
Change in substantial holding |
30 July 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
02 July 24 |
Application for quotation of securities - SPL
×
Application for quotation of securities - SPL |
02 July 24 |
Change in substantial holding
×
Change in substantial holding |
01 July 24 |
Change in Director's Interest Notice - Jeff Davies
×
Change in Director's Interest Notice - Jeff Davies |
28 June 24 |
Change in substantial holding
×
Change in substantial holding |
27 June 24 |
Change in Director's Interest Notice - R Thomas
×
Change in Director's Interest Notice - R Thomas |
27 June 24 |
Change in Director's Interest Notice - L Cheng
×
Change in Director's Interest Notice - L Cheng |
25 June 24 |
Change in substantial holding
×
Change in substantial holding |
21 June 24 |
Change in Director's Interest Notice - R Thomas
×
Change in Director's Interest Notice - R Thomas |
11 June 24 |
Notification regarding unquoted securities - SPL
×
Notification regarding unquoted securities - SPL |
11 June 24 |
DEP presentation at SNMMI radiopharmaceuticals conference
×
DEP presentation at SNMMI radiopharmaceuticals conference |
04 June 24 |
DEP irinotecan presentation at ASCO 2024 Annual Meeting
×
DEP irinotecan presentation at ASCO 2024 Annual Meeting |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.